{"drugs":["Crinone","Endometrin","Prochieve","Progesterone","Prometrium"],"mono":[{"id":"486020-s-0","title":"Generic Names","mono":"Progesterone"},{"id":"486020-s-1","title":"Dosing and Indications","sub":{"0":{"id":"486020-s-1-4","title":"Adult Dosing","mono":"<ul><li>Progesterone intrauterine insert (Progestasert(R)) was discontinued on 06\/01\/2001.<\/li><li><b>Abnormal uterine bleeding unrelated to menstrual cycle:<\/b> 5 to 10 mg IM daily for 6 doses<\/li><li><b>Assisted reproductive technology; Adjunct - Female infertility:<\/b> 90 mg (8% gel) VAGINALLY once or twice daily; if pregnancy occurs, continue treatment until placental autonomy, up to 10 to 12 weeks<\/li><li><b>Assisted reproductive technology; Adjunct - Female infertility:<\/b> 100 mg (vaginal insert) VAGINALLY 2 to 3 times daily starting the day after oocyte retrieval and continuing for up to 10 weeks total duration<\/li><li><b>Contraception:<\/b> 38 mg inserted into the uterus using the inserter provided; remove and replace device every 12 months<\/li><li><b>Endometrial hyperplasia; Prophylaxis:<\/b> 200 mg ORALLY at bedtime for 12 sequential days per 28-day cycle to postmenopausal women with a uterus who are receiving daily conjugated estrogens<\/li><li><b>Secondary physiologic amenorrhea:<\/b> (capsules) 400 mg ORALLY at bedtime for 10 days<\/li><li><b>Secondary physiologic amenorrhea:<\/b> (gel) 4% gel (45 mg) INTRAVAGINALLY every other day up to a total of 6 doses; if no response, may increase to 8% gel (90 mg) INTRAVAGINALLY every other day up to a total of 6 doses<\/li><li><b>Secondary physiologic amenorrhea:<\/b> (injection) 5 to 10 mg IM daily for 6 to 8 days<\/li><li><b>Termination of pregnancy, Reversal, mifepristone-induced:<\/b> repeated doses of 200 mg IM were used in a case series<\/li><li><b>Tocolysis, Maintenance:<\/b> 200 mg orally once daily  OR 400 mg intravaginally once daily at bedtime  until delivery or 37 weeks gestation, whichever occurs earlier (study dosing)<\/li><\/ul>"},"1":{"id":"486020-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Progesterone intrauterine insert (Progestasert(R)) was discontinued on 06\/01\/2001.<\/li><li>safety and effectiveness not established in pediatric patients<\/li><\/ul>"},"3":{"id":"486020-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Progesterone intrauterine insert (Progestasert(R)) was discontinued on 06\/01\/2001.<\/li><li>Abnormal uterine bleeding unrelated to menstrual cycle<\/li><li>Assisted reproductive technology; Adjunct - Female infertility<\/li><li>Contraception<\/li><li>Endometrial hyperplasia; Prophylaxis<\/li><li>Secondary physiologic amenorrhea<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Progesterone intrauterine insert (Progestasert(R)) was discontinued on 06\/01\/2001.<\/li><li>Ischemic heart disease, acute, Exercised-induced<\/li><li>Premature birth of newborn, Short cervix; Prophylaxis<\/li><li>Primary menorrhagia<\/li><li>Termination of pregnancy, Reversal, mifepristone-induced<\/li><li>Tocolysis, Maintenance<\/li><\/ul>"}}},{"id":"486020-s-2","title":"Black Box Warning","mono":"<b>Oral (Capsule, Liquid Filled)<\/b><br\/>Estrogens plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) have been reported with estrogen plus progestin therapy. An increased risk of developing probable dementia in postmenopausal women 65 years of age or older has also been reported. Risks should be assumed to be similar for other doses, combinations, and dosage forms of estrogens and progestins. Progestins with estrogens should be prescribed at the lowest effective doses and for the shortest duration possible.<br\/>"},{"id":"486020-s-3","title":"Contraindications\/Warnings","sub":[{"id":"486020-s-3-9","title":"Contraindications","mono":"<ul><li>allergy to peanuts; contains peanut oil (oral)<\/li><li>arterial thromboembolic disorders, active or history<\/li><li>breast cancer, known, suspected, or history<\/li><li>cerebral apoplexy, current or history of (injection)<\/li><li>ectopic pregnancy (vaginal insert)<\/li><li>genital cancer (injection, vaginal gel)<\/li><li>hypersensitivity to progesterone or other components of the product<\/li><li>liver dysfunction or disease, known<\/li><li>missed abortion (injection, vaginal gel, vaginal insert)<\/li><li>pregnancy, known or suspected (oral)<\/li><li>thromboembolic disorders (eg, deep vein thrombosis, pulmonary embolism), active or history<\/li><li>thrombophlebitis, known or history of (injection, vaginal gel, vaginal insert)<\/li><li>vaginal bleeding, undiagnosed abnormal (oral, injection, vaginal gel)<\/li><\/ul>"},{"id":"486020-s-3-10","title":"Precautions","mono":"<ul><li>breast cancer, invasive; increased risk with use of estrogen plus progestin therapy<\/li><li>cardiovascular disorders (pulmonary embolism, deep vein thrombosis, stroke, and myocardial infarction) have occurred with estrogen plus progestin therapy; immediately discontinue therapy if suspected; increased risk in patients with hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity<\/li><li>dementia, probable, has been reported with estrogen plus progestin therapy; increased risk in postmenopausal women (aged 65 years and older)<\/li><li>addition of a progestin to estrogen therapy; lowers incidence of endometrial hyperplasia in women with a uterus; monitoring recommended, particularly in cases of undiagnosed persistent\/recurring abnormal genital bleeding<\/li><li>concurrent use of other vaginal products; use may alter progesterone release and absorption of drug (vaginal insert, vaginal gel)<\/li><li>depression, history<\/li><li>diabetes; glucose tolerance may be impaired; monitoring recommended<\/li><li>fluid retention may occur; may exacerbate conditions affected by fluid retention (cardiac or renal dysfunction); monitoring recommended<\/li><li>immobilization, prolonged; increased risk of thromboembolism; if possible, discontinue estrogen plus progestin therapy at least 4 to 6 weeks prior (oral)<\/li><li>ovarian cancer; estrogens with progestin therapy may increase risk<\/li><li>retinal vascular thrombosis has been reported with estrogen therapy; temporarily discontinue estrogen plus progestin therapy in cases of sudden partial or complete loss of vision, proptosis, diplopia or migraine; permanently discontinue if papilledema or retinal vascular lesions are detected upon examination<\/li><li>surgeries associated with an increased risk of thromboembolism; discontinuation at least 4 to 6 weeks prior to surgery is recommended (oral)<\/li><li>thrombotic disorders (pulmonary embolism, deep vein thrombosis) may occur; increased risk with personal or family history, obesity, or systemic lupus erythematosus<\/li><\/ul>"},{"id":"486020-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>D (AUS)<\/li><\/ul>"},{"id":"486020-s-3-12","title":"Breast Feeding","mono":"<ul><li>AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},{"id":"486020-s-4","title":"Drug Interactions","sub":{"1":{"id":"486020-s-4-14","title":"Major","mono":"<ul><li>Dabrafenib (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><\/ul>"}}},{"id":"486020-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal pain (oral, 10% to 20%; vaginal gel, 5% to 12%; vaginal insert, 12%), Constipation (oral, 3%; vaginal gel, 27%; vaginal insert, 2% to 3%), Nausea (oral, 5% to 8%; vaginal gel, 6% to 22%; vaginal insert; 7% to 8%), Swollen abdomen (oral, 5% to 12%; vaginal gel, 7% to 13%; vaginal insert, 4%)<\/li><li><b>Immunologic:<\/b>Viral disease (oral, 12%)<\/li><li><b>Musculoskeletal:<\/b>Cramp (vaginal gel, 15% to 26%), Musculoskeletal pain (oral, 12%)<\/li><li><b>Neurologic:<\/b>Dizziness (oral, 5% to 24%; vaginal gel, 5%), Headache (oral, 5% to 31%; vaginal gel, 13% to 19%, vaginal insert, 3% to 4%), Sleep disorder (vaginal gel, 18%), Somnolence (vaginal gel, 27%)<\/li><li><b>Psychiatric:<\/b>Depression (oral, 19%; vaginal gel, 11% to 19%), Mood swings (oral, 5% or more; vaginal gel, 22% to 23%)<\/li><li><b>Renal:<\/b>Nocturia (vaginal gel, 13%)<\/li><li><b>Reproductive:<\/b>Breast tenderness (oral, 5% to 27%), Large breast (vaginal gel, 40%), Pain, Post-oocyte retrieval (vaginal insert, 25% to 28%), Pain of breast (oral, 6% to 16%; vaginal gel, 13%), Perineal pain (vaginal gel, 17%), Vaginal discharge (oral, 10%; vaginal gel, 3% to 11%)<\/li><li><b>Other:<\/b>Fatigue (oral, 5% to 8%; vaginal gel, 21% to 22%; vaginal insert, 2% to 3%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Shock<\/li><li><b>Endocrine metabolic:<\/b>Breast cancer<\/li><li><b>Gastrointestinal:<\/b>Cholecystectomy (oral, 2%), Pancreatitis, acute<\/li><li><b>Hematologic:<\/b>Deep venous thrombosis, Venous thromboembolism<\/li><li><b>Hepatic:<\/b>Cholestasis, Cholestatic hepatitis, Cholestatic jaundice syndrome, Hepatic necrosis, Hepatitis, Jaundice, Liver failure<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction, Anaphylaxis<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident, Ischemic stroke, Transient ischemic attack<\/li><li><b>Ophthalmic:<\/b>Thrombosis of retinal artery<\/li><li><b>Psychiatric:<\/b>Dementia, Suicidal thoughts<\/li><li><b>Reproductive:<\/b>Endometrial carcinoma<\/li><li><b>Respiratory:<\/b>Pulmonary embolism<\/li><li><b>Other:<\/b>Breast cancer, Endometrial carcinoma<\/li><\/ul>"},{"id":"486020-s-6","title":"Drug Name Info","sub":{"0":{"id":"486020-s-6-17","title":"US Trade Names","mono":"<ul><li>Crinone<\/li><li>Prochieve<\/li><li>Prometrium<\/li><li>Endometrin<\/li><\/ul>"},"2":{"id":"486020-s-6-19","title":"Class","mono":"<ul><li>Contraceptive, Local<\/li><li>Endocrine-Metabolic Agent<\/li><li>Female Reproductive Agent<\/li><li>Progestin<\/li><\/ul>"},"3":{"id":"486020-s-6-20","title":"Regulatory Status","mono":"RX\/OTC<br\/>"},"4":{"id":"486020-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"486020-s-7","title":"Mechanism Of Action","mono":"Progesterone is a naturally occurring steroid that transforms proliferative endometrium into a secretory endometrium. It suppresses the secretion of pituitary gonadotropins which inhibits follicular maturation and ovulation.<br\/>"},{"id":"486020-s-8","title":"Pharmacokinetics","sub":[{"id":"486020-s-8-23","title":"Absorption","mono":"<ul><li>Oral, capsule: time to peak concentration, 1.5 h +\/- 0.8 h to 2.3 h +\/- 1.4 h<\/li><li>Vaginal, assisted reproductive technology: time to peak concentration, 3.55 h +\/- 2.48 h to 5.40 h +\/- 0.97 h<\/li><li>Vaginal, secondary amenorrhea: time to peak concentration, 6.67 h +\/- 3.16 h to 7 h +\/- 2.88 h<\/li><li>Bioavailability: (Oral), 10% to 15%<\/li><li>Bioavailability: (Oral, capsule), unknown<\/li><li>Effect of food: increases bioavailability<\/li><\/ul>"},{"id":"486020-s-8-24","title":"Distribution","mono":"Protein binding: approximately 96% to 99% <br\/>"},{"id":"486020-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic<\/li><li>Major metabolites: pregnanediol, 5-beta-pregnan-3alpha, 20-alpha-diol glucuronide, 5-beta-pregnan-3-alpha-ol-20-one (5-beta-pregnanolone) and 5-alpha-pregnan-3-alpha-ol-20-one (5-alpha-pregnanolone)<\/li><\/ul>"},{"id":"486020-s-8-26","title":"Excretion","mono":"<ul><li>Biliary and Fecal: approximately 10%, small portion as unchanged<\/li><li>Renal: 50% to 60% of metabolites<\/li><\/ul>"},{"id":"486020-s-8-27","title":"Elimination Half Life","mono":"<ul><li>(Vaginal), 5 min to 20 min<\/li><li>Assisted reproductive technology: 25.91 h +\/- 6.15 h to 45 h +\/- 34.70 h<\/li><li>Secondary Amenorrhea: 39.08 h +\/- 12.88 h to 49.87 h +\/- 31.20 h<\/li><\/ul>"}]},{"id":"486020-s-9","title":"Administration","mono":"<ul><li><b>Intramuscular<\/b><br\/>inspect injection visually for particulate matter and discoloration prior to administration<br\/><\/li><li><b>Oral<\/b><br\/>women experiencing difficulty swallowing the capsules may take progesterone with a glass of water while in the standing position<br\/><\/li><li><b>Vaginal<\/b><br\/><ul><li>gel, allow at least 6 hours after any other vaginal treatment before using vaginal gel<\/li><li>gel, increasing amount of 4% vaginal gel does not increase the amount of progesterone absorbed; use 8% gel to increase dose<\/li><li>vaginal insert, not recommended for use with other vaginal products<\/li><\/ul><\/li><\/ul>"},{"id":"486020-s-10","title":"Monitoring","mono":"<ul><li>annual history and physical; including blood pressure, cervical cytology and breast exam (in addition to monthly self-exam)<\/li><li>diagnostic measures to rule out malignancy in cases of undiagnosed, persistent\/recurrent abnormal vaginal bleeding<\/li><\/ul>"},{"id":"486020-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Intramuscular Oil: 50 MG\/ML<\/li><li>Oral Capsule, Liquid Filled: 100 MG, 200 MG<\/li><\/ul><\/li><li><b>Crinone<\/b><br\/>Vaginal Gel\/Jelly: 4 %, 8 %<br\/><\/li><li><b>Endometrin<\/b><br\/>Vaginal Tablet: 100 MG<br\/><\/li><li><b>Prometrium<\/b><br\/>Oral Capsule, Liquid Filled: 100 MG, 200 MG<br\/><\/li><\/ul>"},{"id":"486020-s-12","title":"Toxicology","sub":[{"id":"486020-s-12-31","title":"Clinical Effects","mono":"<b>PROGESTINS<\/b><br\/>OVERDOSE:  Rarely do acute ingestions result in obvious clinical manifestations.  CHRONIC: Most  adverse effects are related to chronic or high-dose therapy.  Headache, dizziness, irregular menses, mastalgia, bloating, depression, decreased libido, cholestatic jaundice, hepatitis, oligomenorrhea, amenorrhea and thromboembolism may occur with chronic therapy.<br\/>"},{"id":"486020-s-12-32","title":"Treatment","mono":"<b>PROGESTINS <\/b><br\/><ul><li>Support: Single acute overdoses will seldom result in toxicity.  Supportive treatment is adequate in most situations.<\/li><li>Decontamination: Gastric decontamination is probably only necessary after very large ingestions or with toxic coingestants; administer activated charcoal in these cases.<\/li><li>Monitoring of patient: CHRONIC TOXICITY: Discontinue medication and monitor for signs of toxicity and treat symptomatically.  Obtain a baseline CBC and hepatic and renal function tests in symptomatic patients.<\/li><\/ul>"},{"id":"486020-s-12-33","title":"Range of Toxicity","mono":"<b>PROGESTINS<\/b><br\/>Toxicity is unlikely following an acute overdose.  There are insufficient data reported in the literature to assess the range of toxicity in terms of mg\/kg ingested. <br\/>"}]},{"id":"486020-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may cause dizziness.<\/li><li>Discuss potential long-term adverse effects of hormone therapy including myocardial infarction, stroke, thrombophlebitis, dementia, pulmonary embolism, or breast cancer.<\/li><li>This drug may cause constipation, stomach cramps, headache, mood swings, or painful\/swollen breasts.<\/li><li>Patient should contact healthcare professional if pregnancy is suspected or confirmed. Tell patient to also report unusual vaginal bleeding.<\/li><li>For vaginal form, instruct patient on proper insertion technique. Tell patient to avoid using other vaginal drugs within 6 h before or 6 h after using progesterone.<\/li><li>Patient should not use tampons during therapy.<\/li><\/ul>"}]}